<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D883954B-3A4C-4E5C-9C34-EC54E638DB98"><gtr:id>D883954B-3A4C-4E5C-9C34-EC54E638DB98</gtr:id><gtr:name>Federal University of Santa Maria</gtr:name><gtr:address><gtr:line1>Av. Roraima, 1000</gtr:line1><gtr:postCode>97105-900</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6D374D20-24E8-459F-A9EA-C36A024454A2"><gtr:id>6D374D20-24E8-459F-A9EA-C36A024454A2</gtr:id><gtr:name>Komfo Anokye Teaching Hospital (KATH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4C28AC3-D47A-4238-8BC8-07451E5F0775"><gtr:id>C4C28AC3-D47A-4238-8BC8-07451E5F0775</gtr:id><gtr:name>Obafemi Awolowo University</gtr:name><gtr:address><gtr:line1>PMB 5029</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A86004C8-2B5A-4D93-AFC0-4EC170FE24C6"><gtr:id>A86004C8-2B5A-4D93-AFC0-4EC170FE24C6</gtr:id><gtr:name>Germans University Hospital</gtr:name><gtr:address><gtr:line1>Trias i Pujol</gtr:line1><gtr:line2>Carretera del Canyet</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6A203C73-98D9-456F-BD8B-DFB20233FA27"><gtr:id>6A203C73-98D9-456F-BD8B-DFB20233FA27</gtr:id><gtr:name>Arriaran Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0C422A2E-BE95-4551-BD39-D97589C0B7C6"><gtr:id>0C422A2E-BE95-4551-BD39-D97589C0B7C6</gtr:id><gtr:name>Autonomous University of Barcelona (UAB)</gtr:name><gtr:address><gtr:line1>Edifici CN - Campus 08193 Bellatterra</gtr:line1><gtr:line4>Barcelona</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D54F13C7-6474-4235-ADD6-B318ECCE87BC"><gtr:id>D54F13C7-6474-4235-ADD6-B318ECCE87BC</gtr:id><gtr:name>University of Chile</gtr:name><gtr:address><gtr:line1>Casilla 13578</gtr:line1><gtr:line2>Correo 21</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/044FA7AC-2B61-47DD-BE3F-15E7411CA30C"><gtr:id>044FA7AC-2B61-47DD-BE3F-15E7411CA30C</gtr:id><gtr:name>University Hospital Centre Vaudois</gtr:name><gtr:address><gtr:line1>University Hospital Centre Vaudois</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7EA47BE9-7A59-4B93-8E05-D2A186CD8F28"><gtr:id>7EA47BE9-7A59-4B93-8E05-D2A186CD8F28</gtr:id><gtr:name>Chiang Mai University</gtr:name><gtr:address><gtr:line1>Suthep  Muang</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D883954B-3A4C-4E5C-9C34-EC54E638DB98"><gtr:id>D883954B-3A4C-4E5C-9C34-EC54E638DB98</gtr:id><gtr:name>Federal University of Santa Maria</gtr:name><gtr:address><gtr:line1>Av. Roraima, 1000</gtr:line1><gtr:postCode>97105-900</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6D374D20-24E8-459F-A9EA-C36A024454A2"><gtr:id>6D374D20-24E8-459F-A9EA-C36A024454A2</gtr:id><gtr:name>Komfo Anokye Teaching Hospital (KATH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4C28AC3-D47A-4238-8BC8-07451E5F0775"><gtr:id>C4C28AC3-D47A-4238-8BC8-07451E5F0775</gtr:id><gtr:name>Obafemi Awolowo University</gtr:name><gtr:address><gtr:line1>PMB 5029</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A86004C8-2B5A-4D93-AFC0-4EC170FE24C6"><gtr:id>A86004C8-2B5A-4D93-AFC0-4EC170FE24C6</gtr:id><gtr:name>Germans University Hospital</gtr:name><gtr:address><gtr:line1>Trias i Pujol</gtr:line1><gtr:line2>Carretera del Canyet</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6A203C73-98D9-456F-BD8B-DFB20233FA27"><gtr:id>6A203C73-98D9-456F-BD8B-DFB20233FA27</gtr:id><gtr:name>Arriaran Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0C422A2E-BE95-4551-BD39-D97589C0B7C6"><gtr:id>0C422A2E-BE95-4551-BD39-D97589C0B7C6</gtr:id><gtr:name>Autonomous University of Barcelona (UAB)</gtr:name><gtr:address><gtr:line1>Edifici CN - Campus 08193 Bellatterra</gtr:line1><gtr:line4>Barcelona</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D54F13C7-6474-4235-ADD6-B318ECCE87BC"><gtr:id>D54F13C7-6474-4235-ADD6-B318ECCE87BC</gtr:id><gtr:name>University of Chile</gtr:name><gtr:address><gtr:line1>Casilla 13578</gtr:line1><gtr:line2>Correo 21</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/044FA7AC-2B61-47DD-BE3F-15E7411CA30C"><gtr:id>044FA7AC-2B61-47DD-BE3F-15E7411CA30C</gtr:id><gtr:name>University Hospital Centre Vaudois</gtr:name><gtr:address><gtr:line1>University Hospital Centre Vaudois</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7EA47BE9-7A59-4B93-8E05-D2A186CD8F28"><gtr:id>7EA47BE9-7A59-4B93-8E05-D2A186CD8F28</gtr:id><gtr:name>Chiang Mai University</gtr:name><gtr:address><gtr:line1>Suthep  Muang</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/82CB5BD9-215B-45DE-9EB0-07E1554FB31F"><gtr:id>82CB5BD9-215B-45DE-9EB0-07E1554FB31F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800247"><gtr:id>E2758D74-07B7-4DD4-8332-D1C43E3D2C48</gtr:id><gtr:title>Inter-individual variability in pharmacokinetics and response to protease inhibitor-based antiretroviral therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800247</gtr:grantReference><gtr:abstractText>Treatment for HIV clearly improves survival. However, some patients fail therapy either because of toxicity or because the virus mutates, allowing it to multiply even in the presence of the drug. Both of these factors are strongly influenced by the amount of drug that enters a patient?s bloodstream. For example, too much drug and the patient will experience some types of toxicity and too little drug and the virus is able to try out different mutations, eventually finding those which allow it to survive. Our knowledge of the factors that influence drug concentrations in the blood is rapidly developing. Our recent work has shown that SLCO transporters, which are molecular pumps that transfer anti-HIV drugs into gut and liver cells can influence the absorption and clearance of some drugs from the body. These transporters are encoded by the human genome and there are differences in these genes meaning that in some individuals they have different activity than in others. Therefore, the reason for this research is to assess whether differences in SLCO transporter genes are able to explain some of the differences in drug concentrations and susceptibility to toxicity and failure of anti-HIV drugs. Ultimately, if this project is successful it will aid the development of tests that help HIV doctors to give the right drug, at the right dose to the right patient.</gtr:abstractText><gtr:technicalSummary>The DOH acknowledges that ?pharmacogenomics should help make medicine use more effective?. Drug treatment (costing the NHS #220 million/year) becomes more expensive with each successive failure and Protease inhibitors (PIs) are associated with long term toxicities (e.g. fat redistribution), which are stigmatising but, like acquisition of resistance, are also difficult to reverse. Strategies to improve drug use are therefore needed and Pharmacogenetics offers a way of selecting drugs (by avoiding use in those with highest risk of toxicity) and individualising dosage. Using Xenopus laevis oocyte expression systems we have shown that PIs are substrates for SLCO (OATP) influx transporters. Moreover, in a proof of concept preliminary analysis we have shown a significant association between one common variant of SLCO1B1 (OATP1B1*1b; 521C T) and LPV concentrations in patients. We now propose to utilise high throughput genotyping (Sequenom) of single nucleotide polymorphisms to study associations with drug concentrations (through a therapeutic drug monitoring registry) and clinical response (through the UK CHIC cohort). We will also mine and assess copy number polymorphisms. For polymorphisms associated with response to therapy, we will determine the mechanism in intestinal biopsies (expression) and oocytes (function). Replication of pharmacogenetics studies is paramount and we will also confirm pharmacological phenotype by assessing full pharmacokinetic profiles in patients selected based on their genotype. We plan to gather substantive information on genetic influences associated with response and to assess how this information could be used in clinical practice, by using it to predict durability of LPV, DRV and ATV based regimens.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>339200</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cologne</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Internal Medicine</gtr:department><gtr:description>Cologne</gtr:description><gtr:id>DAABF8E0-FE09-4D16-990D-7FB3F9761979</gtr:id><gtr:impact>The collaboration is multdiciplinary in terms of pharmacology (Liverpool) and clinical (Germany). The collaboation has yielded five research publications to date:

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D. Clin Pharmacol Ther. 2012 Oct;92(4):494-502. doi: 10.1038/clpt.2012.61. Epub 2012 Jul 18. 

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Liptrott NJ, Pushpakom S, Wyen C, F&amp;auml;tkenheuer G, Hoffmann C, Mauss S, Knechten H, Brockmeyer NH, Hopper-Borge E, Siccardi M, Back DJ, Khoo SH, Pirmohamed M, Owen A; German Competence Network for HIV/AIDS. Pharmacogenet Genomics. 2012 Jan;22(1):10-9. doi: 10.1097/FPC.0b013e32834dd82e.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, F&amp;auml;tkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators. J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, F&amp;auml;tkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS. J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

Impact of CYP2B6 983T&amp;gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, F&amp;auml;tkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS. J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.</gtr:impact><gtr:outcomeId>TY2SpT852sK-1</gtr:outcomeId><gtr:partnerContribution>Our clinical collaborators in Germany have and continue to conduct patient recruitment and supply biological material in terms of patient whole blood and plasma. Patient demographic data and data relating to therapy response are also provided.</gtr:partnerContribution><gtr:piContribution>My team and I are conducting genotyping and drug concentration measurements on patients from Cologne and the wider German Competence Network for HIV and AIDS. We also conduct the analysis, interpretation and manuscript writing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Germans Trias i Pujol University Hospital</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Fight Against Aids Foundation (FLS)</gtr:department><gtr:description>Barcelona</gtr:description><gtr:id>3CF2E305-80D5-46E0-8E46-E86F75A4718B</gtr:id><gtr:impact>Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Molt&amp;oacute; J, Rajoli R, Back D, Valle M, Miranda C, Owen A, Clotet B, Siccardi M. J Antimicrob Chemother. 2016 Dec 20. pii: dkw485. doi: 10.1093/jac/dkw485. 

Molt&amp;oacute; J, Xinarianos G, Miranda C, Pushpakom S, Cede&amp;ntilde;o S, Clotet B, Owen A, Valle M. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet. 2013 Jul;52(7):543-53. doi: 10.1007/s40262-013-0057-6.

The collaboration is multidisciplinary and involved pharmacologists (Liverpool), Clinicians (Barcelona) and population pharmacokinetic modellers (Liverpool and Barcelona).</gtr:impact><gtr:outcomeId>nvnsVr7Zixu-1</gtr:outcomeId><gtr:partnerContribution>The partners in Barcelona have and are conducting the clinical recruitment of patients into the studies and population pharmacokinetic analyses that incorporate assessment of demographic factors including genetic factors.</gtr:partnerContribution><gtr:piContribution>My team and I are part of this active collaboration to identify pharmacogenetic associations with antiretroviral protease inhibitors. As such, we have and are conducting genotyping, analysis and interpretation.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Obafemi Awolowo University</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:description>Nigeria</gtr:description><gtr:id>078E5291-FAF1-4B02-AC3F-828C6594DA3E</gtr:id><gtr:impact>The Effect of Gene Variants on Levonorgestrel Pharmacokinetics when Combined with Antiretroviral Therapy containing Efavirenz or Nevirapine. Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, Scarsi KK. Clin Pharmacol Ther. 2017 Feb 10. doi: 10.1002/cpt.667. [Epub ahead of print]

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. Olagunju A, Khoo S, Owen A. Pharmacogenomics. 2016 Jun;17(8):891-906. doi: 10.2217/pgs-2015-0016.

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A.
Pharmacogenet Genomics. 2016 Aug;26(8):381-9. doi: 10.1097/FPC.0000000000000227. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P. Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934.

Class-specific relative genetic contribution for key antiretroviral drugs.
Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A.
J Antimicrob Chemother. 2015 Nov;70(11):3074-9. doi: 10.1093/jac/dkv207. Epub 2015 Jul 28.

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.
Olagunju A, Amara A, Waitt C, Else L, Penchala SD, Bolaji O, Soyinka J, Siccardi M, Back D, Owen A, Khoo S.
J Antimicrob Chemother. 2015 Oct;70(10):2816-22. doi: 10.1093/jac/dkv174. Epub 2015 Jun 24.

Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Adejuyigbe E, Siccardi M, Back D, Khoo S, Owen A.
Clin Infect Dis. 2015 Aug 1;61(3):453-63. doi: 10.1093/cid/civ317. Epub 2015 Apr 16.

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, Oyigboja J, Back D, Khoo S, Owen A.
Clin Pharmacol Ther. 2015 Mar;97(3):298-306. doi: 10.1002/cpt.43. Epub 2015 Jan 20.

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
Olagunju A, Bolaji OO, Amara A, Waitt C, Else L, Soyinka J, Adeagbo B, Adejuyigbe E, Siccardi M, Back D, Owen A, Khoo S.
J Antimicrob Chemother. 2015 Feb;70(2):555-61. doi: 10.1093/jac/dku420. Epub 2014 Oct 17.

CYP3A4*22 (c.522-191 C&amp;gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
Olagunju A, Schipani A, Siccardi M, Egan D, Khoo S, Back D, Owen A.
Pharmacogenet Genomics. 2014 Sep;24(9):459-63. doi: 10.1097/FPC.0000000000000073.

CYP2B6 516G&amp;gt;T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
Olagunju A, Siccardi M, Amara A, Jevtovic D, Kusic J, Owen A, Dragovic G.
Ther Drug Monit. 2014 Dec;36(6):734-8. doi: 10.1097/FTD.0000000000000098.

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.
Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D, Owen A.
In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4. eCollection 2013.

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.
Olagunju A, Owen A, Cressey TR.
Pharmacogenomics. 2012 Oct;13(13):1501-22. doi: 10.2217/pgs.12.138. Review.</gtr:impact><gtr:outcomeId>56dd481b007ee0.15128766-1</gtr:outcomeId><gtr:partnerContribution>All patients are recruited at the partners site and the original studentship was funded from Obafemi Awolowo University.</gtr:partnerContribution><gtr:piContribution>Direct supervision of a PhD student (Adeniyi Olagunju) as well as pharmacokinetic and pharmacogenetic analysis of a cohort of HIV positive pregnant and postpartum women, and their breastfed infants. n, 2)All women were receiving efavirenz or nevirapine based therapy and the collaboration identified 1) differences in pharmacokinetics between pregnant and post partum wome exposure of infants to these drugs via breast milk, and 3) the pharmacogentic determinants of these endpoints. The student has now graduated from their PhD and returned to Nigeria. With out support he was awarded a Wellcome Trust Fellowship in 2017, enabling us to further develop the collaboration. A number of other grant proposals are also in development.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Komfo Anokye Teaching Hospital (KATH)</gtr:collaboratingOrganisation><gtr:country>Ghana, Republic of</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Ghana</gtr:description><gtr:id>58212CF6-7859-4D8A-9D33-C62B9506572D</gtr:id><gtr:impact>Output:

Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, Sarfo MA, Khoo S, Owen A, Chadwick DR. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother. 2014 Feb;69(2):491-9. doi: 10.1093/jac/dkt372.</gtr:impact><gtr:outcomeId>hcNKapyeqnj-1</gtr:outcomeId><gtr:partnerContribution>Dr Sarfo visited my laboratory to conduct collaborative research to assess the impact of host genetic polymorphisms on pharmacokinetics and response to HIV drugs. The collaborators also provided clinical samples for analysis.</gtr:partnerContribution><gtr:piContribution>The Liverpool team provided training and access to laboratories and facilities to conduct an assessment of genetic determinants of pharmacokinetics and response to HIV drugs in Ghana. In subsequent studies, the Liverpool team have led and delivered pharmacokinetic and pharmacogenetic evaluations, as well as statistical analyses and manuscript writing.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Ottawa Health Research Institute</gtr:department><gtr:description>Ottawa</gtr:description><gtr:id>AA7959AA-0D01-4561-9803-4EC96CC8FCA5</gtr:id><gtr:impact>Outputs: 

Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, Porte CJ. Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. Ther Drug Monit. 2012 Nov 20. [Epub ahead of print]

Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010 Sep;65(9):1889-93. Epub 2010 Jul 17

Multidisiplinarity comes from expertise in genetics/gene expression (Liverpool) and clinical/bioanalytical (Ottawa).</gtr:impact><gtr:outcomeId>TzB6XR7CQBn-1</gtr:outcomeId><gtr:partnerContribution>The collaboration allowed us to identify a novel association between CAR polymorphism with efavirenz plasma concentrations and also to assess the contribution of other genetic factors in a resource limited setting (Chile). Beyond this Ottawa are now supplying intestinal biopsies from individuals that recieved lopinavir and ritonavir - samples of this nature are rare and will significantly add to our knowledge of the mechanisms controlling absorption of this important antiretroviral drug.</gtr:partnerContribution><gtr:piContribution>Collaboration was established as a 3-way partnership with Santiago that has resulted in 1 paper and another currently under review. Our group conducts genetic analysis on samples provided by Santiago and bioanalysis (plasma drug concentrations) are monitored in Ottawa. Beyond this, Dr Owen has now established additional collaboration with Ottawa in terms of intestinal biopsies being sent for analysis in Liverpool to assess impact of intestinal expression of drug dispostiion genes on plasma HIV drug concentrations. A manuscript on this second phase of collaboration (not involving Santiago) is now also in preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arriaran Foundation</gtr:collaboratingOrganisation><gtr:country>Chile, Republic of</gtr:country><gtr:description>Santiago</gtr:description><gtr:id>29A03E0D-E50E-4E40-8E3B-7B3C125DA38D</gtr:id><gtr:impact>Output: 
Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, Porte CJ. Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. Ther Drug Monit. 2012 Nov 20. [Epub ahead of print]

Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010 Sep;65(9):1889-93. Epub 2010 Jul 17

Multidisiplinarity comes from genetic (Liverpool) and clinical (Santiago) sites.</gtr:impact><gtr:outcomeId>Hq61Tcsvg1i-2</gtr:outcomeId><gtr:partnerContribution>Identification of a novel association of CAR polymorphism with efavirenz plasma concentrations that is subsequently being assessed in other clinical cohorts in Liverpool. Also, the confirmation of associations with CYP2B6 in resource limited countries broaden the relevance of ongoing research.Identification of a novel association of CAR polymorphism with efavirenz plasma concentrations that is subsequently being assessed in other clinical cohorts in Liverpool. Also, the confirmation of associations with CYP2B6 in resource limited countries broaden the relevance of ongoing research.</gtr:partnerContribution><gtr:piContribution>This collaboration was established as a result of the funding and resulted in a paper published in JAC and another paper that was recently submitted. Clinical samples are now being routinely supplied by the School of Medicine, University of Chile and Fundacio&amp;acute;n Arriara&amp;acute;n, Santiago, Chile. Our group continues to conduct pharmacogenetic studies with samples from Santiago in order to assess the impact on plasma drug concentrations.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>University Hospital Basel</gtr:department><gtr:description>University Hospital Basel</gtr:description><gtr:id>FD16A169-5EE3-4B48-AFE9-66E1AA4488B1</gtr:id><gtr:impact>New collaboration</gtr:impact><gtr:outcomeId>58ca6da09eef70.42982003-1</gtr:outcomeId><gtr:partnerContribution>The partners are contributing complementary knowledge and expertise in terms of clinical perspectives.</gtr:partnerContribution><gtr:piContribution>Our team are leading the physiologically-based pharmacokinetic assessments to further understand and predict pharmacokinetic drug-drug interactions in special populations including pregnancy, paediatrics and aging populations.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Autonomous University of Barcelona (UAB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Barcelona</gtr:description><gtr:id>77712B30-2159-4B38-A68B-730BB7BCDCC3</gtr:id><gtr:impact>Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Molt&amp;oacute; J, Rajoli R, Back D, Valle M, Miranda C, Owen A, Clotet B, Siccardi M. J Antimicrob Chemother. 2016 Dec 20. pii: dkw485. doi: 10.1093/jac/dkw485. 

Molt&amp;oacute; J, Xinarianos G, Miranda C, Pushpakom S, Cede&amp;ntilde;o S, Clotet B, Owen A, Valle M. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet. 2013 Jul;52(7):543-53. doi: 10.1007/s40262-013-0057-6.

The collaboration is multidisciplinary and involved pharmacologists (Liverpool), Clinicians (Barcelona) and population pharmacokinetic modellers (Liverpool and Barcelona).</gtr:impact><gtr:outcomeId>nvnsVr7Zixu-2</gtr:outcomeId><gtr:partnerContribution>The partners in Barcelona have and are conducting the clinical recruitment of patients into the studies and population pharmacokinetic analyses that incorporate assessment of demographic factors including genetic factors.</gtr:partnerContribution><gtr:piContribution>My team and I are part of this active collaboration to identify pharmacogenetic associations with antiretroviral protease inhibitors. As such, we have and are conducting genotyping, analysis and interpretation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Clinical Pharmacology</gtr:department><gtr:description>Baltimore</gtr:description><gtr:id>924A860E-3C7D-4C83-A38F-C515B7CF5CEB</gtr:id><gtr:impact>Williamson B, Dooley KE, Zhang Y, Back D, Owen A. Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampicin, Rifabutin and Rifapentine. Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13.</gtr:impact><gtr:outcomeId>QTQYCxhVnas-1</gtr:outcomeId><gtr:partnerContribution>The collaborators have existing funding for clinical trials in TB. The supplement was awarded to generate data to help rationalise the observations in these trials. The collaborators bring clinical and pharmacological expertise and interpretation while the Liverpool team conducted data generation.</gtr:partnerContribution><gtr:piContribution>As part of a supplement from the US National Institutes of Health a collaboration was initiated to assess the impact of drugs used in the treatment of tuberculosis on expression of drug metabolising enzymes and transporters in primary human hepatocytes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>New South Wales</gtr:description><gtr:id>C88122AA-E273-4D29-A867-F46A548D7925</gtr:id><gtr:impact>Validation of Computational Approaches for Antiretroviral Dose Optimization. Siccardi M, Dickinson L, Owen A.
Antimicrob Agents Chemother. 2016 May 23;60(6):3838-9. doi: 10.1128/AAC.00094-16. 

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Na&amp;iuml;ve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. Clin Pharmacokinet. 2016 Jul;55(7):861-73. doi: 10.1007/s40262-015-0360-5.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Na&amp;iuml;ve HIV-Infected Patients: Results of the ENCORE1 Study. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Winston A, Amin J, Clarke A, Else L, Amara A, Owen A, Barber T, Jessen H, Avihingsanon A, Chetchotisakd P, Khoo S, Cooper DA, Emery S, Puls R; ENCORE Cerebrospinal Fluid (CSF) Substudy Team; ENCORE Cerebrospinal Fluid CSF Substudy Team. Clin Infect Dis. 2015 Apr 1;60(7):1026-32. doi: 10.1093/cid/ciu976.</gtr:impact><gtr:outcomeId>56dd49d980fbb5.41341816-1</gtr:outcomeId><gtr:partnerContribution>The trial was coordinated and administered through the Kirby Institute in New South Wales.</gtr:partnerContribution><gtr:piContribution>A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (ENCORE I). ENCORE1 was a non-inferiority trial in HIV-1-infected antiretroviral-naive adults in 38 clinical sites in 13 countries. Participants were randomly assigned by a computer-generated sequence with a blocking factor of four (stratified by clinical site and by screening viral load) to receive tenofovir plus emtricitabine with either a reduced daily dose (400 mg) or a standard dose (600 mg) of efavirenz. Funded by the Australian Medical Research Council, Professor Owen's team conducted the pharmacokinetic and pharmacogenetics assessments within the trial (including the CNS substudy) that have recently been published. Encore I was the study that demonstrated equivalent efficacy between 400mg and 600mg efavirenz with a reduced incidence of adverse events within the 400mg arm, irrespective of host CYP2B6 genotype. The pharmacokinetic assessment was key to the recent announcement by the World Health Organisation that guidelines will be changed to incorporate the 400mg dose of efavirenz as an alternative first-line option for HIV.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lausanne University Hospital  (CHUV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Division of Clinical Pharmacology and Toxicology</gtr:department><gtr:description>Lausanne</gtr:description><gtr:id>3DCA4AC1-0990-4FC3-A703-B6F9547EADD9</gtr:id><gtr:impact>Outputs:

Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, Owen A, Back D. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013 Jul;52(7):583-92. doi: 10.1007/s40262-013-0056-7. Erratum in: Clin Pharmacokinet. 2013 Jul;52(7):613-4.

Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Boffito M, Owen A, Cavassini M, Guenthard H, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd L, Rotger M, and Csajka C. Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV positive and Healthy Individuals. (2012) Antimicrob Agents Chemother. 56, 2959-66.

The skill sets in Liverpool and Lausanne are similar so the collaboration predominantly serves to cross-validate research findings.</gtr:impact><gtr:outcomeId>hwNN3sTcjC3-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators in Lausanne are working on related topics and we continue to collaborate to progress the field when appropriate.</gtr:partnerContribution><gtr:piContribution>My team and I are conducted genotyping to support data generated in Lausanne for a collaboration. We also contributed to analysis, interpretation and manuscript writing.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turin</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Infectious Diseases</gtr:department><gtr:description>Torino</gtr:description><gtr:id>FD782D9B-19FC-485C-8156-DDB279574625</gtr:id><gtr:impact>Class-specific relative genetic contribution for key antiretroviral drugs.
Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A.
J Antimicrob Chemother. 2015 Nov;70(11):3074-9. doi: 10.1093/jac/dkv207. Epub 2015 Jul 28.

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M, D'Avolio A, Rodriguez-Novoa S, Cuenca L, Simiele M, Baietto L, Calcagno A, Moss D, Bonora S, Soriano V, Back DJ, Owen A, Di Perri G.
Ther Drug Monit. 2012 Apr;34(2):232-5. doi: 10.1097/FTD.0b013e31824aa50a.

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Pushpakom SP, Liptrott NJ, Rodr&amp;iacute;guez-N&amp;oacute;voa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, Khoo S, Pirmohamed M, Owen A.
J Infect Dis. 2011 Jul 1;204(1):145-53. doi: 10.1093/infdis/jir215.

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&amp;gt;C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A.
Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb.

Population pharmacokinetic modeling of the association between 63396C-&amp;gt;T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodr&amp;iacute;guez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A.
Antimicrob Agents Chemother. 2010 Dec;54(12):5242-50. doi: 10.1128/AAC.00781-10. Epub 2010 Oct 4.

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C--&amp;gt;T) with reduced concentrations of unboosted atazanavir.
Siccardi M, D'Avolio A, Baietto L, Gibbons S, Sciandra M, Colucci D, Bonora S, Khoo S, Back DJ, Di Perri G, Owen A.
Clin Infect Dis. 2008 Nov 1;47(9):1222-5. doi: 10.1086/592304.

Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism.
Garcia-Diaz A, Lok CB, Madge S, Booth C, Tyrer M, Bonora S, Mahungu T, Owen A, Johnson M, Geretti AM.
J Antimicrob Chemother. 2008 Dec;62(6):1188-90. doi: 10.1093/jac/dkn374. Epub 2008 Sep 10. Erratum in: J Antimicrob Chemother. 2011 Mar;66(3):688.

The collaboration is multdiciplinary in terms of pharmacology (Liverpool and Torino) and clinical (Torino). The collaboration has yielded four research publications to date with more papers planned for the near future.</gtr:impact><gtr:outcomeId>QYJtUtDhdri-1</gtr:outcomeId><gtr:partnerContribution>Our clinical collaborators in Italy have and continue to conduct patient recruitment, drug concentration analysis and supply biological material in terms of patient whole blood. Patient demographic data and data relating to therapy response are also provided.</gtr:partnerContribution><gtr:piContribution>My team and I are conducting genotyping on patients from Torino. We also contribute to the analysis, interpretation and manuscript writing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiang Mai University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:department>Faculty of Associated Medical Sciences</gtr:department><gtr:description>Chiang Mai</gtr:description><gtr:id>F04F3381-F2F2-40D8-AD5D-42CD68404CD7</gtr:id><gtr:impact>No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
Sirirungsi W, Urien S, Harrison L, Kamkon J, Tawon Y, Luekamlung N, Thongpaen S, Nilmanat A, Jourdain G, Lallemant M, Le Coeur S, Ngo-Giang-Huong N, Owen A, Cressey TR.
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e56-9. doi: 10.1097/QAI.0000000000000504. No abstract available.

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.
Olagunju A, Owen A, Cressey TR.
Pharmacogenomics. 2012 Oct;13(13):1501-22. doi: 10.2217/pgs.12.138.</gtr:impact><gtr:outcomeId>56dd4b20e1b3a1.54409860-1</gtr:outcomeId><gtr:partnerContribution>The Thai collaborators have recruited patients and conducted the pharmacokinetic and pharmacogenetic assessments with guidance from Liverpool.</gtr:partnerContribution><gtr:piContribution>This is an ongoing collaboration with Thailand to validate the pharmacogenetics of antiviral drug pharmacokinetics in Thai patient populations. The Liverpool team have contributed expertise in terms of knowledge of mechanisms that underpin variability in drug exposure.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Chile</gtr:collaboratingOrganisation><gtr:country>Chile, Republic of</gtr:country><gtr:department>School of Medicine Chile</gtr:department><gtr:description>Santiago</gtr:description><gtr:id>9487127D-B9A7-4081-B775-2419DACA740B</gtr:id><gtr:impact>Output: 
Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, Porte CJ. Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. Ther Drug Monit. 2012 Nov 20. [Epub ahead of print]

Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 2010 Sep;65(9):1889-93. Epub 2010 Jul 17

Multidisiplinarity comes from genetic (Liverpool) and clinical (Santiago) sites.</gtr:impact><gtr:outcomeId>Hq61Tcsvg1i-1</gtr:outcomeId><gtr:partnerContribution>Identification of a novel association of CAR polymorphism with efavirenz plasma concentrations that is subsequently being assessed in other clinical cohorts in Liverpool. Also, the confirmation of associations with CYP2B6 in resource limited countries broaden the relevance of ongoing research.Identification of a novel association of CAR polymorphism with efavirenz plasma concentrations that is subsequently being assessed in other clinical cohorts in Liverpool. Also, the confirmation of associations with CYP2B6 in resource limited countries broaden the relevance of ongoing research.</gtr:partnerContribution><gtr:piContribution>This collaboration was established as a result of the funding and resulted in a paper published in JAC and another paper that was recently submitted. Clinical samples are now being routinely supplied by the School of Medicine, University of Chile and Fundacio&amp;acute;n Arriara&amp;acute;n, Santiago, Chile. Our group continues to conduct pharmacogenetic studies with samples from Santiago in order to assess the impact on plasma drug concentrations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Federal University of Santa Maria</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Brazil</gtr:description><gtr:id>0AB5DE20-406A-4E49-BF3C-59F6EFE5143E</gtr:id><gtr:impact>Silva AH, Locatelli C, Filippin-Monteiro FB, Martin P, Liptrott NJ, Zanetti-Ramos BG, Benetti LC, Nazari EM, Albuquerque CA, Pasa AA, Owen A, Creczynski-Pasa TB. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. Toxicol Lett. 2016 Mar 30;246:17-27. doi: 10.1016/j.toxlet.2016.01.018. Epub 2016 Jan 25.</gtr:impact><gtr:outcomeId>56dd45c52140c4.89581702-1</gtr:outcomeId><gtr:partnerContribution>Adny Silva spent a period of 8 months at Liverpool learning various assays for pre-clinical assessment of nanomaterials that were generated by her and her colleagues in Departamento de Ci&amp;ecirc;ncias Farmac&amp;ecirc;uticas, Universidade Federal de Santa Catarina P.O. Box 476, Florian&amp;oacute;polis, SC, 88040-900, Brazil. The Brazilian collaborators therefore generated the materials and helped characterise them in Liverpool. They also co-wrote the two publications.</gtr:partnerContribution><gtr:piContribution>Hosted a visiting scientist from Departamento de Ci&amp;ecirc;ncias Farmac&amp;ecirc;uticas, Universidade Federal de Santa Catarina P.O. Box 476, Florian&amp;oacute;polis, SC, 88040-900, Brazil to undertake the evaluation of novel nanomaterials intended for drug delivery strategies. The Liverpool team provided hands on training and direct research relating to in vitro immunological characterisation, in vitro drug disposition assays and physiologically-based pharmacokinetic modelling. The collaboration has resulted in two publications.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Cape Town</gtr:description><gtr:id>EDFFD318-BEE6-4AE6-9E77-B68A08E48169</gtr:id><gtr:impact>Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P. J Antimicrob Chemother. 2017 Jan;72(1):190-199.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P. Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934.

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Hennig S, Naiker S, Reddy T, Egan D, Kellerman T, Wiesner L, Owen A, McIlleron H, Pym A.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):617-20. doi: 10.1128/AAC.01195-15.

Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.
McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A.
J Infect Dis. 2015 Jun 15;211 Suppl 3:S115-25. doi: 10.1093/infdis/jiu600. Review.

Research capacity. Enabling the genomic revolution in Africa.
H3Africa Consortium, Rotimi C, Abayomi A, Abimiku A, Adabayeri VM, Adebamowo C, Adebiyi E, Ademola AD, Adeyemo A, Adu D, Affolabi D, Agongo G, Ajayi S, Akarolo-Anthony S, Akinyemi R, Akpalu A, Alberts M, Alonso Betancourt O, Alzohairy AM, Ameni G, Amodu O, Anabwani G, Andersen K, Arogundade F, Arulogun O, Asogun D, Bakare R, Balde N, Baniecki ML, Beiswanger C, Benkahla A, Bethke L, Boehnke M, Boima V, Brandful J, Brooks AI, Brosius FC, Brown C, Bucheton B, Burke DT, Burnett BG, Carrington-Lawrence S, Carstens N, Chisi J, Christoffels A, Cooper R, Cordell H, Crowther N, Croxton T, de Vries J, Derr L, Donkor P, Doumbia S, Duncanson A, Ekem I, El Sayed A, Engel ME, Enyaru JC, Everett D, Fadlelmola FM, Fakunle E, Fischbeck KH, Fischer A, Folarin O, Gamieldien J, Garry RF, Gaseitsiwe S, Gbadegesin R, Ghansah A, Giovanni M, Goesbeck P, Gomez-Olive FX, Grant DS, Grewal R, Guyer M, Hanchard NA, Happi CT, Hazelhurst S, Hennig BJ, Hertz- C, Fowler, Hide W, Hilderbrandt F, Hugo-Hamman C, Ibrahim ME, James R, Jaufeerally-Fakim Y, Jenkins C, Jentsch U, Jiang PP, Joloba M, Jongeneel V, Joubert F, Kader M, Kahn K, Kaleebu P, Kapiga SH, Kassim SK, Kasvosve I, Kayondo J, Keavney B, Kekitiinwa A, Khan SH, Kimmel P, King MC, Kleta R, Koffi M, Kopp J, Kretzler M, Kumuthini J, Kyobe S, Kyobutungi C, Lackland DT, Lacourciere KA, Landour&amp;eacute; G, Lawlor R, Lehner T, Lesosky M, Levitt N, Littler K, Lombard Z, Loring JF, Lyantagaye S, Macleod A, Madden EB, Mahomva CR, Makani J, Mamven M, Marape M, Mardon G, Marshall P, Martin DP, Masiga D, Mason R, Mate-Kole M, Matovu E, Mayige M, Mayosi BM, Mbanya JC, McCurdy SA, McCarthy MI, McIlleron H, Mc'Ligeyo SO, Merle C, Mocumbi AO, Mondo C, Moran JV, Motala A, Moxey-Mims M, Mpoloka WS, Msefula CL, Mthiyane T, Mulder N, Mulugeta Gh, Mumba D, Musuku J, Nagdee M, Nash O, Ndiaye D, Nguyen AQ, Nicol M, Nkomazana O, Norris S, Nsangi B, Nyarko A, Nyirenda M, Obe E, Obiakor R, Oduro A, Ofori-Acquah SF, Ogah O, Ogendo S, Ohene-Frempong K, Ojo A, Olanrewaju T, Oli J, Osafo C, Ouwe Missi Oukem-Boyer O, Ovbiagele B, Owen A, Owolabi MO, Owolabi L, Owusu-Dabo E, Pare G, Parekh R, Patterton HG, Penno MB, Peterson J, Pieper R, Plange-Rhule J, Pollak M, Puzak J, Ramesar RS, Ramsay M, Rasooly R, Reddy S, Sabeti PC, Sagoe K, Salako T, Samass&amp;eacute;kou O, Sandhu MS, Sankoh O, Sarfo FS, Sarr M, Shaboodien G, Sidibe I, Simo G, Simuunza M, Smeeth L, Sobngwi E, Soodyall H, Sorgho H, Sow Bah O, Srinivasan S, Stein DJ, Susser ES, Swanepoel C, Tangwa G, Tareila A, Tastan Bishop O, Tayo B, Tiffin N, Tinto H, Tobin E, Tollman SM, Traor&amp;eacute; M, Treadwell MJ, Troyer J, Tsimako-Johnstone M, Tukei V, Ulasi I, Ulenga N, van Rooyen B, Wachinou AP, Waddy SP, Wade A, Wayengera M, Whitworth J, Wideroff L, Winkler CA, Winnicki S, Wonkam A, Yewondwos M, sen T, Yozwiak N, Zar H.
Science. 2014 Jun 20;344(6190):1346-8. doi: 10.1126/science.1251546. No abstract available.

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H.
Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7. doi: 10.1128/AAC.01833-10.

The collaboration is multidisciplinary involving pharmacogenetics and in vitro expertise from my laboratory and clinical and population pharmacokinetic modelling expertise from Cape Town. Other publications are also currently in progress and the collaboration has been expanded to include genetic analysis in a number of additional ongoing clinical trials.</gtr:impact><gtr:outcomeId>iX3dEkYHuz6-1</gtr:outcomeId><gtr:partnerContribution>This collaboration has expanded my clinical collaborations thereby allowing access to clinical specimens and accelerating my pharmacogenetic research.</gtr:partnerContribution><gtr:piContribution>On the back of this research funding we have developed assays that allow us to investigate the influence of SLCO transporters for other relevant pharmacological agents. This has allowed us to expand our network of collaborations. One particularly important collaboration has been established with Dr Helen McIlleron in Cape Town, South Africa. Together we have begun to assess the influence of SLCO1B1 polymorphisms on the pharmacokinetics and response to rifampicin, rifabutin and rifapentin in tuberculosis infected patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>2bio 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>494042ED-0EBF-4815-9DED-BC9B86C5973F</gtr:id><gtr:impact>Approximately 50 representatives from local businesses attended this talk about how our research may interface with what their commercial ambitions. The talked sparked interest and discussion and interfaced with a networking event run on the same evening.

The potential for collaboration is now being discussed with a number of attendees.</gtr:impact><gtr:outcomeId>iEhHxHuETfS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IFARA interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1F78DC4C-16BF-4B58-8E8D-B5284B40AFC3</gtr:id><gtr:impact>A podcast interview that was published online at http://www.ifarablog.org/2010/02/pharmacogenetics-upcoming-applications.html

Patients requested additional information about pharmacogenetic research in HIV</gtr:impact><gtr:outcomeId>YuZDsNtQFhd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Little Big Medicine 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>231A1559-440C-4E8F-8D8E-2145426B08F8</gtr:id><gtr:impact>The University of Liverpool event was co-ordinated with ISTH meeting. Approximately 60 teachers and pupils attended this talk on our scientific research (layman language). The talk preceded a formalised question, answer and discussion session with which the audience (particularly the pupils) fully engaged.

A huge level of interest was received from the students at the event and this was evidenced by lots of extremely well informed and logical questions from the pupils during the Q&amp;amp;A. As a result of the session, two students request work experience in my laboratory over the summer period.</gtr:impact><gtr:outcomeId>nJpxyFLv2Tf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wales Gene Park</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>771B739D-A00A-4BBB-89C6-98E6A2DD8811</gtr:id><gtr:impact>A public engagement lay presentation on the role of pharmacogenetics in tailoring infectious diseases therapy.</gtr:impact><gtr:outcomeId>58ca6fc64d4e21.22026528</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1210035</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Towards complete sustained release nanoformulations of NRTI based regimens</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>National Institutes of Health Clinical Center</gtr:fundingOrg><gtr:fundingRef>R01AI114405</gtr:fundingRef><gtr:id>19294052-2B27-49C0-B5A9-E9487D49DD6B</gtr:id><gtr:outcomeId>56dd4df6e630d7.28592857</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pharmacogenetic predictors of antiretroviral drugs pharmacokinetics, efficacy and safety during pregnancy and lactation</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Obafemi Awolowo University</gtr:fundingOrg><gtr:id>3082C8C2-4B65-419E-9061-3533FFF2B385</gtr:id><gtr:outcomeId>546205249e32c3.93887771</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>878569</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Nanoscale Drug Delivery Systems and their Application to HIV/AIDS treatment</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I038721/1</gtr:fundingRef><gtr:id>E6B03BBB-2948-4F4B-A976-48BC2ADE4C7D</gtr:id><gtr:outcomeId>ZqgjAefSk46</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of an Antiviral Powder that forms a Nanodispersion on Addition to Water</gtr:description><gtr:fundingOrg>IOTA Nanosolutions Limited</gtr:fundingOrg><gtr:id>BEDB6294-5D95-4F06-B8A2-096E54C02C5C</gtr:id><gtr:outcomeId>oDy9n9owQND</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>119942</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigation of the role of ABCB5 in corticosteroid transport and response in IBD</gtr:description><gtr:fundingOrg>National Association for Colitis and Crohn?s Disease (NACC)</gtr:fundingOrg><gtr:id>1C51DF97-F793-4F1B-AB35-CE9E106D75A9</gtr:id><gtr:outcomeId>ZJtfrFwsJ4U0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>317353</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Health and Medical Research Council</gtr:department><gtr:description>A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with stardard dose EFV</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Australian Government</gtr:fundingOrg><gtr:id>FDFD3AB8-3B5D-486C-85BA-47CE62B063BF</gtr:id><gtr:outcomeId>Bgd2jqXE5hp</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1120609</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Responsive Mode Grant</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>4EE18EAF-FC5E-4588-826C-3C0DF9F98C05</gtr:id><gtr:outcomeId>XE4ieDc1pRp0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143878</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Raltegravir pharmacokinetics</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>C72713DE-97C8-4234-AEAA-B6550CA81299</gtr:id><gtr:outcomeId>54620642e73254.55771155</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>808127</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Towards complete sustained release nanoformulations of NRTI based regimens</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>321BA5BC-B7D1-4911-B777-9ADF02B451FF</gtr:id><gtr:outcomeId>54620455c14167.59832021</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1333141</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Towards NanoMedicine Interventions for HIV/AIDS</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K002201/1</gtr:fundingRef><gtr:id>3D333B2F-0ED9-445E-B28A-8DA4C9724F21</gtr:id><gtr:outcomeId>CSotSw17RmR</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98758</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Antiepileptic drug transport at the blood-brain barrier; more than just P-glycoprotein</gtr:description><gtr:fundingOrg>Epilepsy Research UK</gtr:fundingOrg><gtr:id>CF4CC1EF-9D79-46D5-A4BE-3F1F7601E6D6</gtr:id><gtr:outcomeId>bKJMipd2UqZ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16551</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Ind Partnership case studentship.</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>F9D35BC9-2CCC-48FD-9A28-3C221CBA19A2</gtr:id><gtr:outcomeId>546208a2e1c3e6.16498065</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18800</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Host susceptibility to EVF-associated treatment limiting toxicity in the German competence Network. (Kurztitel: &amp;quot;KompNet-GenTox-Study&amp;quot;)</gtr:description><gtr:fundingOrg>Competence Network for HIV/AIDS</gtr:fundingOrg><gtr:id>24559CB5-D86F-4B9C-8E61-B9B6F4E93ED9</gtr:id><gtr:outcomeId>VyfePuoWgod</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>58500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Modulation of bioavailability via tissue specific induction of metabolising enzyme and transporter proteins by ritonavir and other drugs.</gtr:description><gtr:end>2007-03-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>BC70B022-94E0-4368-9AA1-BFCCC75713F2</gtr:id><gtr:outcomeId>54620fc1323184.89962580</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2004-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Assessment of drug and system parameters for quantitative predictions of drug-drug interactions (DDIs) arising from induction of drug metabolising enzymes and drug transporters</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>SimCyp Ltd</gtr:fundingOrg><gtr:id>F9A7BEFB-EC70-4973-8ACB-23B063ED767C</gtr:id><gtr:outcomeId>546206eaae06e6.53693454</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Application of nanomedicine to childhood diseases</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Alder Hey Children's NHS Foundation Trust</gtr:fundingOrg><gtr:id>A946C5F9-2384-4DD4-8A67-B309D1688121</gtr:id><gtr:outcomeId>mzM4KXXVmxi</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24116</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE studentship</gtr:description><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:fundingRef>AZ217862</gtr:fundingRef><gtr:id>694FB606-A4D0-44D8-8E9B-ED4858269A2B</gtr:id><gtr:outcomeId>Ny3MHG1odE3</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Influence of genetic polymorphisms on antiretroviral pharmacokinetics</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F25D8361-A1B5-4E72-B68F-013924DE1A20</gtr:id><gtr:outcomeId>5462069834b921.91566455</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78012</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bridging and accelerating the translation of novel scientific findings for health and wealth gain</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E9E1AD93-5043-4C30-9C09-2BFC280C95F7</gtr:id><gtr:outcomeId>546203f83262f5.07111173</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1320</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Assessment of the impact of host genetic variation on the response to lopinavir-containing regimens in HIV+ patients.</gtr:description><gtr:end>2006-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>E7613447-B3E6-4DBB-B8CD-96A117F7A122</gtr:id><gtr:outcomeId>54620c34b6aeb4.16623962</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19675</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pharmacogenetic and functional analysis of novel GSTP1 polymorphism.</gtr:description><gtr:end>2007-01-02</gtr:end><gtr:fundingOrg>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>FA26903E-8E10-4298-B660-2A061B598C1F</gtr:id><gtr:outcomeId>54620c981fb3c9.07574693</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2005-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>999975</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TAILoR</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D1C69F93-0E05-479D-89CF-AE0F277C2AC2</gtr:id><gtr:outcomeId>WmcWmScd1k80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Monument Trust</gtr:department><gtr:description>Pharmacogenetic and pharmacokinetic studies.</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>The Sainsbury Family Charitable Trusts</gtr:fundingOrg><gtr:id>F8558D32-8B68-421D-BF44-F5D38F2F81A6</gtr:id><gtr:outcomeId>54620ab30f08b8.32220542</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>503485</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health Clinical Center</gtr:fundingOrg><gtr:fundingRef>R24AI118397</gtr:fundingRef><gtr:id>E39BCF46-D4E2-414B-A58B-13FAC478068E</gtr:id><gtr:outcomeId>56dd4ecf17ecc3.83318240</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28754</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Factors influencing drug absorption from small bowel.</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>5A98A12D-7999-487B-AFB5-FBBFAB37E995</gtr:id><gtr:outcomeId>54620903c3e587.20352553</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78030</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Tibotec</gtr:department><gtr:description>Assessing the intracellular accumulation of TMC114 and other Tibotec Compounds.</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>7E791E67-ED3C-4199-B003-4E3FCB1658C2</gtr:id><gtr:outcomeId>5462097852b0e5.52715139</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2005-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1422399</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery</gtr:description><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G066272/1</gtr:fundingRef><gtr:id>877E408E-ACE4-4E27-952E-3CAEE2DA5AFA</gtr:id><gtr:outcomeId>X4xzJDyShDU</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Interactions between chemokine receptor antagonists and other drugs.</gtr:description><gtr:end>2006-06-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>96F3B16D-76C7-4C3A-9811-D46953764C14</gtr:id><gtr:outcomeId>54620f7de6cc82.42484818</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2004-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93064</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TDF combination solid drug nanoparticles</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Clinton Health Access Initiative (CHAI)</gtr:fundingOrg><gtr:id>1DE6EE1F-5503-4C5B-84B8-630992BA49F2</gtr:id><gtr:outcomeId>54620562d89df8.79793794</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>265086</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EURIPIDES - EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>201380</gtr:fundingRef><gtr:id>80F95E75-98EA-4160-AF03-5316DC373737</gtr:id><gtr:outcomeId>QHXnuiY1y5z</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4203686</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Antiretroviral therapy (ART) simplification</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>United States Agency for International Development</gtr:fundingOrg><gtr:fundingRef>AID-OAA-A-15-00069</gtr:fundingRef><gtr:id>C0843FEC-CBC2-4F25-811C-D741B7E3E8A8</gtr:id><gtr:outcomeId>56dd4f3246f094.97527875</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>896475</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Integrated radiomaterials chemistry for simultaneous multi-component tracking of nanomedicines in biological matrices</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>4C2AEEDE-822C-41BC-B88D-DAF0F84C5924</gtr:id><gtr:outcomeId>546204afb8a6a9.61849187</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>154266</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Modulation of TB-HIV drug interaction by host genetic influences</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C277979D-9C97-4381-8C18-7A4F149DF75B</gtr:id><gtr:outcomeId>rnzHXsu9k9Q0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>932728</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Liverpool Imaging Partnership: Molecular physiology and drug response</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2767115D-3C88-4EAA-B505-19857681F904</gtr:id><gtr:outcomeId>54620735253fe5.24320230</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>355752</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Inter-individual variability in pharmacokinetics and response to protease inhibitor-based antiretroviral therapy.</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4E858A4E-F981-4F9E-A464-D524CF68CDA7</gtr:id><gtr:outcomeId>546207a49b1ae6.14897817</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90906</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>University Hospital Basel</gtr:department><gtr:description>Computational models for the prediction of PK in special populations</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>University of Basel</gtr:fundingOrg><gtr:id>428EC946-D1F3-479B-90C5-51D76230871E</gtr:id><gtr:outcomeId>58ca6c28b3e321.51861659</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>123163</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>Prediction of drug-drug interaction between Rifampicin and Boosted Darunavir using pharmacokinetic modelling approaches</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>9762423E-E0CF-41A0-A408-3CAEFAA67D6D</gtr:id><gtr:outcomeId>546205f8cfcdd6.90645824</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99583</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pickering-stabilised Nanoemulsions as Novel Antiretroviral Drug Delivery Systems</gtr:description><gtr:fundingOrg>British Society for Antimicrobial Chemotherapy</gtr:fundingOrg><gtr:id>994CB479-D440-4970-AD0F-6D07A0900085</gtr:id><gtr:outcomeId>Kf4BsosfM4S</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>432281</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Solid drug nanoparticles</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Viiv Healthcare</gtr:fundingOrg><gtr:id>0CD88FAD-EFA7-49B9-ACF7-7CC98741EC78</gtr:id><gtr:outcomeId>56dd4d8ce58622.51890673</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>645058</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Nanotechnology Characterisation Laboratory</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>654190</gtr:fundingRef><gtr:id>C8E069A8-F0C5-4EB8-926C-9BF48C0E0ACA</gtr:id><gtr:outcomeId>56dd4e6c94f398.19679248</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81392</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cellular determinants of raltegravir exposure</gtr:description><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>69EEE688-1FE2-447C-8FDD-569EF66E4930</gtr:id><gtr:outcomeId>Grxy4hgs8ja</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88511</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of solid drug nanoparticle for treatment of tuberculosis</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>F19AC6AF-2408-4E49-82E9-22666DA109F4</gtr:id><gtr:outcomeId>tNXxRQqNk4n</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Vacation Scholarship: Influence of genetic polymorphisms on antiretroviral pharmacokinetics</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>ACE5EFC5-10D3-410D-853A-0C70C519B3E3</gtr:id><gtr:outcomeId>Qmop4LRW47q</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a porous composite material comprising a hydrophilic carrier carrying a magnetic material. The porous composite material can include a hydrophobic polymer, hydrophobic material, organic compound, and/or pharmaceutically active ingredient. The porous composite material is prepared by a modified emulsion templating and freeze-drying procedure. Magnetic nanoparticles are released from the porous composite material on application of water.</gtr:description><gtr:grantRef>G0800247</gtr:grantRef><gtr:id>D0241C4B-2A80-49DB-AA6E-8FE8A19AB2FA</gtr:id><gtr:impact>Published this month</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>VS6mYZbHbvz</gtr:outcomeId><gtr:patentId>WO2012143733</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Magnetic nanoparticles</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a porous composite material comprising a hydrophilic carrier carrying a magnetic material. The porous composite material can include a hydrophobic polymer, hydrophobic material, organic compound, and/or pharmaceutically active ingredient. The porous composite material is prepared by a modified emulsion templating and freeze-drying procedure. Magnetic nanoparticles are released from the porous composite material on application of water.</gtr:description><gtr:grantRef>G0800247</gtr:grantRef><gtr:id>DED182A5-7D1A-46AF-A4D6-FC2C9A22038C</gtr:id><gtr:impact>The patent application was marketed and latterly allowed to lapse</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-8831558543.100542766af4ec</gtr:outcomeId><gtr:patentId>WO2012143733</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>NANOPARTICLES</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid compn. and an aq. dispersion comprising nanoparticles of the antiretroviral drugs lopinavir and ritonavir. The solid compn. and aq. dispersion addnl. comprise a mixt. of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol 12-hydroxystearate, polyvinyl alc., and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alc. (PVA), a polyvinyl alc.-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl Me cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for prepg. both the solid compn. and the aq. dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>G0800247</gtr:grantRef><gtr:id>C5DCF6A3-F47F-4ED8-8322-A6A2D4C278C6</gtr:id><gtr:impact>Much interest in this patent application as part of a larger portfolio and negotiations to progress to human trials are ongoing</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-7927802631.5642557667498c</gtr:outcomeId><gtr:patentId>WO2013034927</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR AND RITONAVIR</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>G0800247</gtr:grantRef><gtr:id>35AF431C-5B77-4DC2-A4FB-CDED53E4E130</gtr:id><gtr:impact>The patent is supporting a human clinical trial and has initiated interest from global charities and the NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-9728776486.337908766747c0</gtr:outcomeId><gtr:patentId>WO2013034925</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF EFAVIRENZ</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).</gtr:description><gtr:grantRef>G0800247</gtr:grantRef><gtr:id>76BF1248-701A-4B34-9A91-AA24E04C8E9E</gtr:id><gtr:impact>This patent is underpinning a human clinical trial and has attracted considerable global interest from charities and NIH (US)</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-9422826356.648306766748a6</gtr:outcomeId><gtr:patentId>WO2013034926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMPOSITIONS OF LOPINAVIR</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have expanded our access to DNA and plasma from HIV+ patients. The sample bank and database now contain data and samples for cohorts from Chile, Germany, Italy, UK, Spain, South Africa, Ghana and Thailand (&amp;gt;3000 samples).</gtr:description><gtr:id>957C40C5-22B1-4F65-87A5-1E5BF430EF06</gtr:id><gtr:impact>The database and samples have had a huge impact upon our pharmacogenetics reseaarch and outputs. The PI has co-authored 27 papers since establishing the clinical links that were greatly facilitated by the current grant.</gtr:impact><gtr:outcomeId>qTEGCmuXbw1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Pharmacogenetics database</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have been the sole provider of therapeutic drug monitoring in the UK (and beyond) since 2002. This has reulted in the archiving of samples and data from &amp;gt;12000 TDM requests across multiple antiretroviral drugs. This grant has enabled us to establish a TDM registry with anonomysed database to accellerate pharmacogenetics research.</gtr:description><gtr:id>3308E7AB-3BCC-4063-9500-DE4573658E7D</gtr:id><gtr:impact>The registry provides a tool for rapid assessment of putative pharmacogenetic associations enabling us to quickly validate our in vitro studies with a clinical endpoint - a strategy that has resulted in multiple publications to date.</gtr:impact><gtr:outcomeId>qjemU8zFCSx</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TDM registry</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Sequenom based assays have been developed to capture 95% of the genetic variability across the SLCO family of transporters. The assays include an analysis of tagging SNPs supplemented with SNPs of known and of putative functional significance.</gtr:description><gtr:id>A8CC53B4-C371-4252-ADEE-EC08ED13B004</gtr:id><gtr:impact>Successful development of these assays has resulted in studies to assess the impact of these polymorphisms on antiretroviral drugs but has also led to a new collaboration in South Africa to establish the importance of these variants for antituberculosis drugs. The assays have also been shared with other research groups in Liverpool and are being employed for analysis in other disease areas.</gtr:impact><gtr:outcomeId>VdSFShFKxJv</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Sequenom based assays for genotyping 260 SNPs across the SLCO transporter gene family</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>X. Laevis oocyte expression systems have been developed for OATP1A2, OATP1B1, OATP1B3 and OATP3A1. Models have also been developed for functional genetic variants of these transporters.</gtr:description><gtr:id>1A53A45F-63CE-4E5B-88F7-FE9CBDC18E5A</gtr:id><gtr:impact>The OATP transporters continue to emerge as important determinants of the pharmacokinetics of many different drug classes across most disease areas. These tools have been utilised for antiretrovirals within this project and this has so far resulted in two publications. Ongoing work is now applying these models to other infectious disease agents and the models have also been provided to other research groups in Liverpool as part of projects in epilepsy, colitis and cancer.</gtr:impact><gtr:outcomeId>NLr7cYxgexJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>OATP expressing oocyte expression systems</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Tandem Nano Ltd</gtr:companyName><gtr:description>Tandem Nano Ltd is a nanoformulation company aiming to improve the action, delievry, use and behaviour of poorly soluble compounds</gtr:description><gtr:id>01FEFEC4-D0D9-42ED-AA65-EE1332E3EAE1</gtr:id><gtr:impact>Currently negotiating meaningful interactions with numerous global companies</gtr:impact><gtr:outcomeId>545e5d71c4eb79.08211231</gtr:outcomeId><gtr:url>http://www.tandemnano.com/</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>1A13771B-79AD-4797-A3D1-689718B683D4</gtr:id><gtr:title>CYP3A4*22 (c.522-191 C&amp;gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>5461f3ae5e3e15.28517678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5869BCC3-7B8E-4168-8725-17AE3290FDBA</gtr:id><gtr:title>Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea37e8ffe1157d60bbee55da70b82122"><gtr:id>ea37e8ffe1157d60bbee55da70b82122</gtr:id><gtr:otherNames>Molt? J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>pm_12815_25_23494984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FF9CBEC-9F5E-4B6D-8C11-B888C6515432</gtr:id><gtr:title>Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea7486cbf57532b700b369c945cd7974"><gtr:id>ea7486cbf57532b700b369c945cd7974</gtr:id><gtr:otherNames>Nelson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56d99812d8d149.74739207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>291C9993-72BA-46A9-969D-62F8D84BD8DF</gtr:id><gtr:title>Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_22082652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AF141E1-C04E-410B-B548-6B6E844EA953</gtr:id><gtr:title>Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5192223c24ed03f7cd25d22e2e6759c1"><gtr:id>5192223c24ed03f7cd25d22e2e6759c1</gtr:id><gtr:otherNames>Wyen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_21715435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1690BBE8-FF71-4E2E-8390-D661E92FBE64</gtr:id><gtr:title>Is methanol really a bad solvent for poly(n-butyl methacrylate)? Low dispersity and high molecular weight polymers of n-butyl methacrylate synthesised via ATRP in anhydrous methanol</gtr:title><gtr:parentPublicationTitle>Polym. Chem.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c10d7eaffc5e77010f8d32d89f4c29a8"><gtr:id>c10d7eaffc5e77010f8d32d89f4c29a8</gtr:id><gtr:otherNames>Dwyer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f3aed73f34.29877772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2D63782-F37D-4E98-BCE8-584035894EB2</gtr:id><gtr:title>The role of drug transporters in the kidney: lessons from tenofovir.</gtr:title><gtr:parentPublicationTitle>Frontiers in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1663-9812</gtr:issn><gtr:outcomeId>56d99813c253e8.68593801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F931EEA-0AD5-4C00-9303-FCFD7CC422BB</gtr:id><gtr:title>Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>pm_12815_25_23057550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1759B49-9C99-4D0A-BEF5-9A3A7CDB035C</gtr:id><gtr:title>Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.</gtr:title><gtr:parentPublicationTitle>HIV clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79fe36361f535508157a8c42393da972"><gtr:id>79fe36361f535508157a8c42393da972</gtr:id><gtr:otherNames>Haas DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1528-4336</gtr:issn><gtr:outcomeId>pm_12815_25_22180526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F987891-CBA6-4505-A12D-78C44F44775C</gtr:id><gtr:title>Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Na&amp;iuml;ve HIV-Infected Patients: Results of the ENCORE1 Study.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>56d99810488a98.04919875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>705F8FA7-CDF2-402F-9678-B4E3710CC98D</gtr:id><gtr:title>Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>5461f566dfae34.69742301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89F05FD8-1236-4AB3-BA16-221A59206737</gtr:id><gtr:title>Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06b8bfbbf7c5f9349931d4f38f3cbde2"><gtr:id>06b8bfbbf7c5f9349931d4f38f3cbde2</gtr:id><gtr:otherNames>Taylor S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_22169189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6D404AB-C754-46EB-A782-665F812B5271</gtr:id><gtr:title>Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5461f566925a65.61541622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73B0D624-345F-40A9-BB7B-5A0BCB891F8C</gtr:id><gtr:title>Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields.</gtr:title><gtr:parentPublicationTitle>Nanoscale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2040-3364</gtr:issn><gtr:outcomeId>58ca7b71640422.60722484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AB13603-899F-4E24-B5C2-8B4542BE8229</gtr:id><gtr:title>The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76796f3ea56696c7017727d7ffcb6d46"><gtr:id>76796f3ea56696c7017727d7ffcb6d46</gtr:id><gtr:otherNames>Bienczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>58ca7f6f89aca7.68587981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AAE70B4-5CC0-4D91-9EC6-66D19DC6E295</gtr:id><gtr:title>Regulation of CYP3A4 and CYP3A5 expression and modulation of &amp;quot;intracrine&amp;quot; metabolism of androgens in prostate cells by liganded vitamin D receptor.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b15b2f3a7933d3cb2ea5b23da6e1bc7b"><gtr:id>b15b2f3a7933d3cb2ea5b23da6e1bc7b</gtr:id><gtr:otherNames>Maguire O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>5461f3af58df42.21176080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AF7597E-FC51-4D38-9B29-ACFB2732DC6F</gtr:id><gtr:title>Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_12815_25_22477766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11281056-1744-4F73-82ED-A765470D6C13</gtr:id><gtr:title>New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/817eda19ac6c2a80aef0b19b6f166780"><gtr:id>817eda19ac6c2a80aef0b19b6f166780</gtr:id><gtr:otherNames>Boffito M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>5461f3afaba9c0.73901294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50CA4766-729D-49D6-AB60-15FC3BFE5185</gtr:id><gtr:title>Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aba5e9bae9a56a3e6b33f6cf48ec89fa"><gtr:id>aba5e9bae9a56a3e6b33f6cf48ec89fa</gtr:id><gtr:otherNames>Tatham LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>56d998121300f5.07351613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>765203A7-B902-4FFC-80AC-FDACD8573D63</gtr:id><gtr:title>Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b85ee323b50a8e7c01e965c3546c48"><gtr:id>f9b85ee323b50a8e7c01e965c3546c48</gtr:id><gtr:otherNames>Curley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>58ca7f6ef18e64.02132463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22427A74-C0A8-4FB0-91BC-7B5706FA8E4F</gtr:id><gtr:title>Class-specific relative genetic contribution for key antiretroviral drugs.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56d998135dfeb3.19481768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6052675B-DBBB-47ED-9118-269C2A0B0022</gtr:id><gtr:title>Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>58ca7f6fef49d9.26280468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>991DD652-FF33-4090-8460-18BF38F9EE0B</gtr:id><gtr:title>Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12815_25_23011396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>405E3318-E00F-41A1-826B-A5ED762AA66F</gtr:id><gtr:title>HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a115960aa50380c50c0fbcd79cbae81"><gtr:id>4a115960aa50380c50c0fbcd79cbae81</gtr:id><gtr:otherNames>Hartkoorn RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_20051929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36C2B6F0-3442-47AD-BEBC-D28773F06D59</gtr:id><gtr:title>Adipogenic gene variants in patients with HIV-associated lipodystrophy.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_21178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEBC9F61-DBAD-4BA8-B2D4-379AC0B6CFB4</gtr:id><gtr:title>Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_21441248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3A081CD-4637-4EF9-853C-B4F5DDD0D55A</gtr:id><gtr:title>Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>pm_12815_25_22406652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>848DDDA5-24FC-426D-8CD9-3877CCD95D6B</gtr:id><gtr:title>Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76796f3ea56696c7017727d7ffcb6d46"><gtr:id>76796f3ea56696c7017727d7ffcb6d46</gtr:id><gtr:otherNames>Bienczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58ca7f6dce6211.59875608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8EFCA35-CAB4-46E2-92F1-71C511132B1D</gtr:id><gtr:title>Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5461f5664662f8.44566617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A3008B2-AEC0-443C-8561-1C9902CD4799</gtr:id><gtr:title>The application of nanotechnology in medicine: treatment and diagnostics.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5461f185701027.13335890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD8571D-423F-4E38-ADA2-F9CA66A1A593</gtr:id><gtr:title>Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d19dd5a51d1cf4ff43003c1c9e4cf808"><gtr:id>d19dd5a51d1cf4ff43003c1c9e4cf808</gtr:id><gtr:otherNames>Naisbitt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56d9980f90fea4.34490181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A1026C4-1CFA-460B-BB3F-1D08D20CCD1C</gtr:id><gtr:title>Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e416bae170c240b44fc3ec50d0becb21"><gtr:id>e416bae170c240b44fc3ec50d0becb21</gtr:id><gtr:otherNames>Okoli C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5461f3ae84e744.49890979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD75578E-075D-4DDE-8886-30436FE046C2</gtr:id><gtr:title>Transport of gabapentin by LAT1 (SLC7A5).</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b33a890e90d14fa3124761f64d50024"><gtr:id>5b33a890e90d14fa3124761f64d50024</gtr:id><gtr:otherNames>Dickens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>5461f3af7fbcd6.90731938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B29D893C-96BD-4D83-9E2C-B66CF1D4DC48</gtr:id><gtr:title>Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6ba0d23000695e55f65d009993928e1"><gtr:id>f6ba0d23000695e55f65d009993928e1</gtr:id><gtr:otherNames>Sandkovsky U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58ca7f6e3347a1.48580934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCDBBA67-DC05-41DC-869B-2D96F8379EC1</gtr:id><gtr:title>IFN-? 874A&amp;gt;T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patients.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12815_25_21926633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1499F69-563F-48F5-BA80-2148A7B63062</gtr:id><gtr:title>RXR? gene variants are associated with HIV lipodystrophy.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_23759678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9A584E0-6B38-4CAA-BC69-7EC54E868B6D</gtr:id><gtr:title>Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f185a10da7.50732130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07B4A6AC-41E0-4108-B588-873916436317</gtr:id><gtr:title>ABCB1 single nucleotide polymorphisms (1236C&amp;gt;T, 2677G&amp;gt;T, and 3435C&amp;gt;T) do not affect transport activity of human P-glycoprotein.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b33a890e90d14fa3124761f64d50024"><gtr:id>5b33a890e90d14fa3124761f64d50024</gtr:id><gtr:otherNames>Dickens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_23619510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8315AA54-C419-4FE6-A5E0-3A6F0C287D45</gtr:id><gtr:title>A multi-system approach assessing the interaction of anticonvulsants with P-gp.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b33a890e90d14fa3124761f64d50024"><gtr:id>5b33a890e90d14fa3124761f64d50024</gtr:id><gtr:otherNames>Dickens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5461f185276168.06780040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF87C6FD-856A-49DC-9874-E40623F3DE76</gtr:id><gtr:title>Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ec6b554f4908332610be3529ea65fae"><gtr:id>8ec6b554f4908332610be3529ea65fae</gtr:id><gtr:otherNames>Kigen G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12815_25_21373194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6832511F-E902-49D9-84F7-2CAFF7F70030</gtr:id><gtr:title>Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons.</gtr:title><gtr:parentPublicationTitle>Soft matter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da41dd096107cf69341fe1fc68839d6c"><gtr:id>da41dd096107cf69341fe1fc68839d6c</gtr:id><gtr:otherNames>Rogers HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1744-683X</gtr:issn><gtr:outcomeId>56d9980fd952a6.85788474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FE8286F-DDAA-4F56-A690-8F7530C3713C</gtr:id><gtr:title>Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_20639527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>389BE6B0-DE22-4F2E-9EC3-7A8D89B86353</gtr:id><gtr:title>Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>56d9981063fa96.38264842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD53368-C95A-4D17-AD3B-5F5505DCC3CD</gtr:id><gtr:title>Validation of Computational Approaches for Antiretroviral Dose Optimization.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>58ca7f6fc80534.66347608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F52C6B31-55C6-421D-BD34-7201C10EC399</gtr:id><gtr:title>Special issue of BJP on nanomedicine.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5461f185d7e363.14731215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9360B2D5-E042-4CE6-B325-9786846F821B</gtr:id><gtr:title>Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c55bff97465fc86ce9da667f9962f42"><gtr:id>2c55bff97465fc86ce9da667f9962f42</gtr:id><gtr:otherNames>Hennig S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>56d9980f527109.24049535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>785CF278-BA0F-436F-8CA2-69812D8D55F5</gtr:id><gtr:title>Population pharmacokinetic modeling of the association between 63396C-&amp;gt;T pregnane X receptor polymorphism and unboosted atazanavir clearance.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_20921307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59A75339-3DED-4C5C-BE06-BB5982FAC8B7</gtr:id><gtr:title>Genetics and Evolution of Infectious Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c88a2dc4d7afe91f5a97b569476428"><gtr:id>03c88a2dc4d7afe91f5a97b569476428</gtr:id><gtr:otherNames>Mahungu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>9780123848901</gtr:isbn><gtr:outcomeId>56d99814a6a665.58725944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC027A50-FEAB-48CF-AC8A-DD6A81688B30</gtr:id><gtr:title>A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5461f566b96438.33794493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7685C498-C120-4C19-BC87-229BC70C2EF6</gtr:id><gtr:title>Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_21078936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>818455CE-0FCB-41AB-9F80-87E11DBFC4E4</gtr:id><gtr:title>Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>pm_12815_25_23479398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B6CDB13-E4BE-42FD-AF4C-767D1BC4D8C9</gtr:id><gtr:title>Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and A-B Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media</gtr:title><gtr:parentPublicationTitle>Macromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a75ead6a36ef5b2f4f39fc1e5178cfe3"><gtr:id>a75ead6a36ef5b2f4f39fc1e5178cfe3</gtr:id><gtr:otherNames>Ford J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d99812481742.23831328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B5E9B2D-27F5-450D-9A01-18981C539C64</gtr:id><gtr:title>Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents</gtr:title><gtr:parentPublicationTitle>Chem. Sci.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a218872932a4524de9fd3083c441f4"><gtr:id>b9a218872932a4524de9fd3083c441f4</gtr:id><gtr:otherNames>Hatton F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f3aead23f8.30248141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C25EE906-06C2-40BA-A39D-37E5DDF702EA</gtr:id><gtr:title>Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c3014fb05d742a33b2bce4c411aed89"><gtr:id>1c3014fb05d742a33b2bce4c411aed89</gtr:id><gtr:otherNames>Elliot E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58ca7b70f19bf4.29215473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B56B9B8E-587E-4B5C-B979-A724CD09373B</gtr:id><gtr:title>The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef0ff72d8f751f869ac5c94305431e2"><gtr:id>2ef0ff72d8f751f869ac5c94305431e2</gtr:id><gtr:otherNames>Janneh O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>56d99814c5e333.32484430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28BB8427-3587-4F82-AAAC-CAC38FE0C838</gtr:id><gtr:title>Predicting intestinal absorption of raltegravir using a population-based ADME simulation.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_23515248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C9E72AC-565F-4BDF-BF0B-630B369FE8F5</gtr:id><gtr:title>Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bd1f04acbef2c60a76e7c6f98d210e"><gtr:id>07bd1f04acbef2c60a76e7c6f98d210e</gtr:id><gtr:otherNames>McIlleron H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56d9981003b435.44867418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29F30680-462E-4AE8-9F68-7491F9068919</gtr:id><gtr:title>Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5461f1854dd935.11354382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1FEED68-5E55-4175-92E5-52BA386CB0E2</gtr:id><gtr:title>Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba720e7977ae1eb8d42c164b75f4324b"><gtr:id>ba720e7977ae1eb8d42c164b75f4324b</gtr:id><gtr:otherNames>Arab-Alameddine M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_22371894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF53382E-A3F7-4ACA-B262-1DE9939703B7</gtr:id><gtr:title>Pharmacogenetics of antiretroviral agents.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>pm_12815_15_19372981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89A6BB0A-18F9-49BC-A526-418A2C48F9D2</gtr:id><gtr:title>Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>5461f5660da367.28049668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C35352FA-3EC7-4F35-8052-320E1DC4AFB8</gtr:id><gtr:title>Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f966db23a09b19b29dbbcba992446889"><gtr:id>f966db23a09b19b29dbbcba992446889</gtr:id><gtr:otherNames>Sarfo FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_24080498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4EF6A17-502D-4752-B3F9-74992269BBD3</gtr:id><gtr:title>Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12815_25_21628669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>273C8E7F-8DDD-4C69-A21F-1BC11A6577D1</gtr:id><gtr:title>Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma.</gtr:title><gtr:parentPublicationTitle>HIV clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0ef047e8cc1399cfe8d6bbfa601b9ad"><gtr:id>e0ef047e8cc1399cfe8d6bbfa601b9ad</gtr:id><gtr:otherNames>McFaul K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1528-4336</gtr:issn><gtr:outcomeId>58ca7f6eb02360.50081395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>439180C6-E741-4E31-8891-FA424A9FF8DC</gtr:id><gtr:title>Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_24002095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F5D0F0B-2FB0-4A1A-BB5D-F7C8B7303A2E</gtr:id><gtr:title>Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>58ca7f6f401bf9.11967643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C5806F-9B68-4F35-9141-89E65B48B75B</gtr:id><gtr:title>Nanoengineering</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>9780444627476</gtr:isbn><gtr:outcomeId>56d9980fb25953.67313547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD853AC-C851-4023-A9A0-201A75146152</gtr:id><gtr:title>Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ef4bc924b19c7e189b6f654810964e"><gtr:id>68ef4bc924b19c7e189b6f654810964e</gtr:id><gtr:otherNames>Doyle T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12815_25_22238167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D6C70F-950B-441F-B8F2-8D71079095EA</gtr:id><gtr:title>The relationships of ABCB1 3435C&amp;gt;T and CYP2B6 516G&amp;gt;T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb24e13619b2628a397627c17fc2f2ec"><gtr:id>bb24e13619b2628a397627c17fc2f2ec</gtr:id><gtr:otherNames>Mahungu TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_12815_15_19474786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAEB6DEF-2469-436C-A87B-2EEB3BA0AE59</gtr:id><gtr:title>Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>pm_540e15ce15c811af9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BED951B-A6D8-4F83-B265-3CAB7CDE37C0</gtr:id><gtr:title>CYP2B6 516G&amp;gt;T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>5461f5666d1c58.57696985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0424C1B0-2E08-4D42-BF6C-168B0433656C</gtr:id><gtr:title>Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&amp;gt;C polymorphism.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_12815_25_21217360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F6C831B-CFAE-4A44-807A-7C41E2C6F975</gtr:id><gtr:title>Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_12815_25_23794601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C868AC2E-FC48-451E-B37C-083DC284C479</gtr:id><gtr:title>The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn><gtr:outcomeId>pm_12815_25_21299442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEACD8FF-F880-4069-B23B-E28D150DF4DD</gtr:id><gtr:title>Divalent metals and pH alter raltegravir disposition in vitro.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_22450971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B218BBEB-92B9-41D2-8C8A-7C235EF54943</gtr:id><gtr:title>Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ef4ee6414a84691ea3291e9a427df54"><gtr:id>5ef4ee6414a84691ea3291e9a427df54</gtr:id><gtr:otherNames>Cortes CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>pm_12815_25_23172109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33B93538-9C0D-4F99-A121-8CE27C2F63DB</gtr:id><gtr:title>Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>585d33359742b8.84404244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCD86167-B7E5-4AE1-9868-40526B2CD2D6</gtr:id><gtr:title>Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56d9980f734342.17395202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140630B9-117A-4374-AD8C-7CEBB34046BC</gtr:id><gtr:title>Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef0ff72d8f751f869ac5c94305431e2"><gtr:id>2ef0ff72d8f751f869ac5c94305431e2</gtr:id><gtr:otherNames>Janneh O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56d99815527587.52653446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>787E094F-33E5-4A9D-88DD-199912366CE6</gtr:id><gtr:title>Lamotrigine is a substrate for OCT1 in brain endothelial cells.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b33a890e90d14fa3124761f64d50024"><gtr:id>5b33a890e90d14fa3124761f64d50024</gtr:id><gtr:otherNames>Dickens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>5461f184c90eb6.92928870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ABF9FFC-F76B-4717-8EA7-69A58BD40A0F</gtr:id><gtr:title>Emerging nanomedicine applications and manufacturing: progress and challenges.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e7e2fee983614ddb80b7213d567913"><gtr:id>30e7e2fee983614ddb80b7213d567913</gtr:id><gtr:otherNames>Sartain F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>58ca7b7139d5d7.21361348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B61EA7A3-A4D7-4884-A33F-EE33343A41D6</gtr:id><gtr:title>Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA.</gtr:title><gtr:parentPublicationTitle>Xenobiotica; the fate of foreign compounds in biological systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9bdfee87c8018d4536157eda87453e9"><gtr:id>b9bdfee87c8018d4536157eda87453e9</gtr:id><gtr:otherNames>Williamson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-8254</gtr:issn><gtr:outcomeId>pm_12815_25_23461378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F974F65-25BE-46BB-98BC-ACE2D88FDF06</gtr:id><gtr:title>Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9bdfee87c8018d4536157eda87453e9"><gtr:id>b9bdfee87c8018d4536157eda87453e9</gtr:id><gtr:otherNames>Williamson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_24060875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8566750E-9F4C-45D8-B836-AEFC4200EA86</gtr:id><gtr:title>Research capacity. Enabling the genomic revolution in Africa.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc1b9c3a30bb27ac4ad84839a2dd9c24"><gtr:id>cc1b9c3a30bb27ac4ad84839a2dd9c24</gtr:id><gtr:otherNames>H3Africa Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56d99813e0c6d3.15534566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8FC0643-152A-4E5B-8AE5-018F8C14B017</gtr:id><gtr:title>Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da9ddb181833c4cb9246f504b868cb60"><gtr:id>da9ddb181833c4cb9246f504b868cb60</gtr:id><gtr:otherNames>Kwan WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_12815_15_19740394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>333C9C23-B688-4E0C-9AE2-9E4672AEF572</gtr:id><gtr:title>High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f3af0c77b7.31499381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>676CB9A0-B2CD-4ADC-9C10-236942CFF5DB</gtr:id><gtr:title>Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism</gtr:title><gtr:parentPublicationTitle>Journal of Antimicrobial Chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1474f78223e8e8dd5451d3cf71fa2939"><gtr:id>1474f78223e8e8dd5451d3cf71fa2939</gtr:id><gtr:otherNames>Garcia-Diaz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>56d9981487a2c4.08113737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6105D8FD-DDF5-4D11-9E14-7C3813F1B0C2</gtr:id><gtr:title>Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles.</gtr:title><gtr:parentPublicationTitle>Toxicology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83cc501a05c1cc8c20ca697e44ffdf9d"><gtr:id>83cc501a05c1cc8c20ca697e44ffdf9d</gtr:id><gtr:otherNames>Silva AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>58ca7b719d3e55.36257508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFE6E173-96C7-416B-8187-45E463023C32</gtr:id><gtr:title>Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d4c2f57f6f7c6e7b09cbfa839e2119c"><gtr:id>1d4c2f57f6f7c6e7b09cbfa839e2119c</gtr:id><gtr:otherNames>Geretti AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12815_25_23874928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A98B9148-71F0-4307-9C49-598F91FFA087</gtr:id><gtr:title>Cytochrome P450 2B6 516G--&amp;gt;T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c88a2dc4d7afe91f5a97b569476428"><gtr:id>03c88a2dc4d7afe91f5a97b569476428</gtr:id><gtr:otherNames>Mahungu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_12815_15_19228205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C30DB55A-ACD9-4EA7-9595-FF8D4C2890D8</gtr:id><gtr:title>Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d99813825631.06408352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15418E3C-ACA0-4BC8-8A67-2A13072D0D7D</gtr:id><gtr:title>Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b85ee323b50a8e7c01e965c3546c48"><gtr:id>f9b85ee323b50a8e7c01e965c3546c48</gtr:id><gtr:otherNames>Curley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>58ca7f6da056e7.80784207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>443AF78E-A533-4492-B137-9C0AE8D6F633</gtr:id><gtr:title>The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936be8fe289660558eed2b8dc4f61ee3"><gtr:id>936be8fe289660558eed2b8dc4f61ee3</gtr:id><gtr:otherNames>Liptrott NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>56d998150f5c12.31528067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0D8C7CC-C3A9-4B88-9CE5-EA37F55545DA</gtr:id><gtr:title>Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.</gtr:title><gtr:parentPublicationTitle>Advanced healthcare materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0417a44a7ef591b40114351d26ff40bb"><gtr:id>0417a44a7ef591b40114351d26ff40bb</gtr:id><gtr:otherNames>McDonald TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2192-2640</gtr:issn><gtr:outcomeId>pm_540e15ce15c8a5c90</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3D91BFA-6DE7-4BCB-B8FD-58848A171E21</gtr:id><gtr:title>Considerations for clinically-relevant nanomedicine therapies for chronic diseases.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1d6d619c42388d8cdb238501bb7319"><gtr:id>cf1d6d619c42388d8cdb238501bb7319</gtr:id><gtr:otherNames>Owen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>56d998131c1795.10897435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3204D028-960D-40F4-ADF5-CDDA73FB6AE8</gtr:id><gtr:title>No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff742d17ec2576b43c53e4c1aa3a3fb7"><gtr:id>ff742d17ec2576b43c53e4c1aa3a3fb7</gtr:id><gtr:otherNames>Sirirungsi W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56d99811e1c3f2.25758629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4501505-28B6-41C2-852B-FC31F5F6220B</gtr:id><gtr:title>Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e1d141212a6e34d7ccdcca71f83b111"><gtr:id>1e1d141212a6e34d7ccdcca71f83b111</gtr:id><gtr:otherNames>Rodr?guez-N?voa S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_12815_15_19400747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38CC58C7-81D6-4341-88F0-E662A164E459</gtr:id><gtr:title>Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>58ca7f6f1a2f34.06335032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E26C4C93-4166-4D05-AE02-DEB6C30A560E</gtr:id><gtr:title>Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abef285ce4934bcd5c2290018958e8ec"><gtr:id>abef285ce4934bcd5c2290018958e8ec</gtr:id><gtr:otherNames>Hatton FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>56d99812a96f50.86314407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA1B02B-0892-4AE7-B54C-DA63E5A5D013</gtr:id><gtr:title>Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e855f713559d0f11c6dc4c71c220ac34"><gtr:id>e855f713559d0f11c6dc4c71c220ac34</gtr:id><gtr:otherNames>Rajoli RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>56d998102a0108.18818999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A879174-38E4-44E3-8B4F-99E7DEC495DC</gtr:id><gtr:title>Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600&amp;nbsp;mg in Treatment-Na&amp;iuml;ve HIV-Infected Patients at 96&amp;nbsp;Weeks: Results of the ENCORE1 Study.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>56d998133cefd4.97785674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>185707C7-1C11-4DD2-B621-363C1C6CBD56</gtr:id><gtr:title>The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4094d0f4db85bb308125f0986165afa"><gtr:id>a4094d0f4db85bb308125f0986165afa</gtr:id><gtr:otherNames>Chigutsa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_12815_25_21709081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E021E38-6D01-48A3-97C8-AADFCF40B84D</gtr:id><gtr:title>Nanomedicines for HIV therapy.</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn><gtr:outcomeId>5461f565d91cd2.69466539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB545BD8-7108-4A02-AFBF-4AE81C71A1D1</gtr:id><gtr:title>Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65da67b16bc5ccd9ce1b330b734b99ed"><gtr:id>65da67b16bc5ccd9ce1b330b734b99ed</gtr:id><gtr:otherNames>Siccardi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_12815_25_22805423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9560024-2CE0-461A-9E32-7900B040A8EB</gtr:id><gtr:title>The impact of pharmacogenetics on HIV therapy.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb24e13619b2628a397627c17fc2f2ec"><gtr:id>bb24e13619b2628a397627c17fc2f2ec</gtr:id><gtr:otherNames>Mahungu TW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>pm_12815_15_19255258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D952E1DF-668A-428D-A59C-B7E1B3A3FB3D</gtr:id><gtr:title>Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching</gtr:title><gtr:parentPublicationTitle>Green Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f3af316e18.53708414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82C0A87B-F275-4313-B872-81846516125B</gtr:id><gtr:title>Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5866bff6b7be8772b0bc13c9117fba67"><gtr:id>5866bff6b7be8772b0bc13c9117fba67</gtr:id><gtr:otherNames>Alfirevic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>56d99812692e37.95412537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2270A451-A286-4B10-9920-D45A304FFED3</gtr:id><gtr:title>Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58ca7f6e8540b1.75521082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92FDFBAC-4C9D-4413-9A05-0CB1AE8BC46E</gtr:id><gtr:title>Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56d99813a0fdb6.56130740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1320089A-E2D1-4C19-A141-0CB53DD79F7F</gtr:id><gtr:title>Facile synthesis of complex multi-component organic and organic-magnetic inorganic nanocomposite particles</gtr:title><gtr:parentPublicationTitle>Journal of Materials Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/236f8fefb1de42b371cef64a9fd83257"><gtr:id>236f8fefb1de42b371cef64a9fd83257</gtr:id><gtr:otherNames>Giardiello M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5461f184f13289.60308510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E05A7D02-895B-4782-830D-1F5529F8F44B</gtr:id><gtr:title>Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems</gtr:title><gtr:parentPublicationTitle>Advanced Functional Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722518fc75cb6d2dd93af953554f8a4f"><gtr:id>722518fc75cb6d2dd93af953554f8a4f</gtr:id><gtr:otherNames>McDonald T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5461f565aadda4.01863438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E07A0C1-0884-453C-844B-375976919B8A</gtr:id><gtr:title>Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.</gtr:title><gtr:parentPublicationTitle>Acta pharmacologica Sinica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aebd9fcdb75ba6a10430e6f39a62dd8"><gtr:id>8aebd9fcdb75ba6a10430e6f39a62dd8</gtr:id><gtr:otherNames>Martin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1671-4083</gtr:issn><gtr:outcomeId>56d99814e06ed9.41856565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>701B751B-90BD-49F0-94C1-6F539D53FEC6</gtr:id><gtr:title>Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter.</gtr:title><gtr:parentPublicationTitle>Frontiers in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4755fe90517ba2ba3199dc82e04f781"><gtr:id>b4755fe90517ba2ba3199dc82e04f781</gtr:id><gtr:otherNames>Moss DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1663-9812</gtr:issn><gtr:outcomeId>56d998128b2d31.71030329</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800247</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>